Reported value
$6.9B
2026 Q2 filing
| Ticker | Company | Weight | Shares | Change |
|---|---|---|---|---|
| GH | Guardant Health, Inc. | 7.41% | 3,393,312 | ADDED (+1.6%) |
| IMVT | Immunovant, Inc. | 5.24% | 9,341,151 | TRIMMED (-19.0%) |
| GPCR | STRUCTURE THERAPEUTICS INC | 3.70% | 4,740,072 | ADDED (+10.8%) |
| PCVX | Vaxcyte, Inc. | 3.64% | 4,300,000 | HELD |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 3.61% | 825,000 | NEW |
| MANE | Veradermics, Inc | 3.58% | 2,000,000 | ADDED (+300.0%) |
| TARS | TARSUS PHARMACEUTICALS INC | 3.36% | 3,666,768 | ADDED (+1.9%) |
| ALKS | Alkermes plc. | 3.05% | 4,000,000 | ADDED (+11.4%) |
| OCUL | OCULAR THERAPEUTIX INC | 2.81% | 19,686,282 | HELD |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 2.75% | 3,307,481 | ADDED (+187.6%) |
| NRIX | NURIX THERAPEUTICS INC | 2.73% | 7,736,455 | ADDED (+21.9%) |
| ORKA | Oruka Therapeutics, Inc. | 2.67% | 1,926,000 | TRIMMED (-5.3%) |
| ALMS | ALUMIS INC | 2.60% | 6,348,558 | TRIMMED (-6.3%) |
| IONS | IONIS PHARMACEUTICALS INC | 2.54% | 2,200,000 | ADDED (+12.8%) |
| CMPS | COMPASS Pathways plc | 2.50% | 12,161,496 | HELD |
| VERA | VERA THERAPEUTICS INC | 2.50% | 4,000,000 | TRIMMED (-2.6%) |
| AXSM | Axsome Therapeutics, Inc. | 2.49% | 700,000 | TRIMMED (-36.4%) |
| GMAB | GENMAB A/S | 2.26% | 5,650,000 | ADDED (+54.2%) |
| MLTX | MOONLAKE IMMUNOTHERAPEUTICS | 1.98% | 6,999,025 | ADDED (+9.2%) |
| COAG | HEMAB THERAPEUTICS HOLDINGS | 1.93% | 3,602,093 | NEW |
| TNGX | TANGO THERAPEUTICS INC | 1.91% | 4,200,000 | ADDED (+52.7%) |
| DFTX | DEFINIUM THERAPEUTICS INC | 1.88% | 2,750,000 | TRIMMED (-8.3%) |
| GRAL | GRAIL, Inc. | 1.82% | 1,834,944 | ADDED (+6.5%) |
| BCAX | BICARA THERAPEUTICS INC | 1.77% | 4,100,000 | ADDED (+0.9%) |
| MAZE | MAZE THERAPEUTICS INC | 1.62% | 3,732,569 | ADDED (+7.3%) |
| CLDX | Celldex Therapeutics, Inc. | 1.59% | 2,939,151 | ADDED (+128.9%) |
| LBRX | LB PHARMACEUTICALS INC | 1.58% | 3,352,804 | HELD |
| MBX | MBX BIOSCIENCES INC | 1.39% | 1,732,569 | TRIMMED (-37.2%) |
| GHRS | GH Research PLC | 1.30% | 3,333,334 | NEW |
| COGT | COGENT BIOSCIENCES INC | 1.13% | 2,000,000 | ADDED (+100.0%) |
| UTHR | UNITED THERAPEUTICS Corp | 0.97% | 123,616 | NEW |
| AVTX | AVALO THERAPEUTICS INC | 0.97% | 3,610,000 | NEW |
| VRDN | Viridian Therapeutics, Inc.\DE | 0.96% | 3,592,740 | ADDED (+157.7%) |
| CYTK | CYTOKINETICS INC | 0.87% | 700,000 | TRIMMED (-49.1%) |
| ALT | Altimmune, Inc. | 0.85% | 19,250,000 | NEW |
| PSNL | Personalis, Inc. | 0.78% | 4,000,000 | ADDED (+33.3%) |
| ACRS | ACLARIS THERAPEUTICS INC | 0.72% | 9,345,000 | HELD |
| CRMD | CORMEDIX INC | 0.72% | 6,274,076 | HELD |
| WGS | GeneDx Holdings Corp. | 0.70% | 700,000 | NEW |
| HROW | HARROW INC | 0.60% | 969,000 | NEW |
| CRVS | CORVUS PHARMACEUTICALS INC | 0.54% | 2,491,939 | HELD |
| SLDB | SOLID BIOSCIENCES INC | 0.52% | 3,565,062 | HELD |
| BEAM | Beam Therapeutics Inc. | 0.50% | 1,000,000 | ADDED (+21.8%) |
| DYN | DYNE THERAPEUTICS INC | 0.48% | 1,500,000 | TRIMMED (-25.0%) |
| IMMX | IMMIX BIOPHARMA INC | 0.42% | 2,775,000 | NEW |
| XFOR | X4 PHARMACEUTICALS INC | 0.40% | 5,878,757 | TRIMMED (-7.3%) |
| STTK | SHATTUCK LABS INC | 0.37% | 3,706,734 | NEW |
| MNKD | MANNKIND CORP | 0.37% | 6,000,000 | NEW |
| IPSC | CENTURY THERAPEUTICS INC | 0.34% | 9,462,645 | TRIMMED (-0.3%) |
| GENB | GENERATE BIOMEDICINES INC | 0.33% | 1,333,815 | NEW |
| VSTM | Verastem, Inc. | 0.32% | 5,740,850 | HELD |
| KURA | Kura Oncology, Inc. | 0.32% | 1,978,565 | TRIMMED (-25.2%) |
| ENTA | ENANTA PHARMACEUTICALS INC | 0.31% | 1,444,167 | TRIMMED (-26.2%) |
| NKTR | NEKTAR THERAPEUTICS | 0.30% | 300,000 | NEW |
| OLMA | Olema Pharmaceuticals, Inc. | 0.27% | 1,500,000 | NEW |
| KLRA | KAILERA THERAPEUTICS INC | 0.22% | 700,000 | NEW |
| KARD | KARDIGAN INC | 0.21% | 600,000 | NEW |
| ELVN | ENLIVEN THERAPEUTICS INC | 0.17% | 225,000 | NEW |
| PMN | PROMIS NEUROSCIENCES INC | 0.16% | 835,655 | HELD |
| IMCR | IMMUNOCORE HOLDINGS PLC-ADR | 0.14% | 311,218 | TRIMMED (-83.9%) |
| XNCR | XENCOR INC | 0.14% | 593,551 | NEW |
| CNTX | CONTEXT THERAPEUTICS INC | 0.06% | 7,419,355 | HELD |
| IVA | INVENTIVA SA - ADR | 0.04% | 800,000 | TRIMMED (-34.6%) |
| ALGS | ALIGOS THERAPEUTICS INC | 0.04% | 444,110 | HELD |
The weights above sum to 94.5% of the fund’s reported 13F value. Only positions matched to a U.S.-listed ticker are listed; the remainder sits in unmatched or non-equity positions in the filing.
Exited this quarter: ANIP, BBIO, BLLN, CBIO, GERN, JANX, LRMR, XBI.
Source: SEC Form 13F filing for the quarter ended Jun 30, 2026, filed Aug 14, 2026. CIK 0001856083. Change labels compare with the fund’s previous quarterly filing. 13F filings cover long positions only.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.